PDS Biotechnology (NASDAQ:PDSB) Given “Buy” Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB) in a research report sent to investors on Friday morning,Benzinga reports. HC Wainwright currently has a $21.00 price target on the stock.

Several other analysts have also recently commented on the stock. StockNews.com cut shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, November 9th. Alliance Global Partners upgraded shares of PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, PDS Biotechnology currently has an average rating of “Moderate Buy” and an average price target of $12.33.

PDS Biotechnology Price Performance

PDS Biotechnology stock opened at $2.01 on Friday. The business has a 50 day simple moving average of $3.21 and a 200-day simple moving average of $3.26. PDS Biotechnology has a 12 month low of $1.53 and a 12 month high of $6.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 3.84 and a quick ratio of 3.84. The stock has a market capitalization of $74.01 million, a PE ratio of -1.73 and a beta of 1.93.

Institutional Trading of PDS Biotechnology

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in PDS Biotechnology by 5.5% in the first quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock valued at $6,288,000 after buying an additional 82,135 shares in the last quarter. Blair William & Co. IL grew its holdings in shares of PDS Biotechnology by 204.4% in the 2nd quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock worth $357,000 after acquiring an additional 81,743 shares during the period. Cubist Systematic Strategies LLC purchased a new position in PDS Biotechnology in the 2nd quarter valued at approximately $146,000. XTX Topco Ltd raised its holdings in PDS Biotechnology by 241.8% during the third quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock worth $257,000 after purchasing an additional 47,528 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in PDS Biotechnology during the second quarter worth $120,000. Institutional investors and hedge funds own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.